Angiogenesis inhibition, long studied in the treatment of malignancies, has begun to emerge as a potential therapeutic approach in managing inflammatory arthritis, particularly rheumatoid arthritis.

An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

Particularly noteworthy among these compounds are 6-gingerol and 6-shogaol, which have been recognized for their potent anticancer properties. These compounds work through several mechanisms, notably ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Existing treatments for endometriosis have changed little in the past 30 years and are often ineffective or have undesired ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 24.55%, which has investors questioning if this is right time to ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline ...